放射性^131I治疗甲亢性心脏病的临床价值

Radioiodine-131 for treatment of thyrotoxic cardiopathy

目的探讨放射性核素^131I治疗甲状腺功能亢进（甲亢）性心脏病的疗效及临床价值。方法对82例甲亢性心脏病患者的临床资料进行回顾性分析。结果甲状腺弥漫性肿大者58例，无明显肿大者24例。甲亢伴甲亢性心脏病患者治疗前与治疗后3、6、12个月时血清FT3、FT4、sTSH、TCA、TMA水平差异均有统计学意义（t=2．03～4．17，均P〈0．05）；而治疗后3、6、12个月时血清各项指标间的差异均无统计学意义（t=1．37—1．89；均P〉0．05）。甲亢性心脏病的治愈率为76．8％（63／82），有效率89．0％（73／82）。结论^131I是治疗甲亢性心脏病的较理想方法。

Objective To probe the treatment value of radioiodine-131 for thyrotoxic cardiopathy. Methods The clinical data of 82 patients of thyrotoxic cardiopathy were analyzed retrospectively. Results There were 58 patients with thyroid gland diffusely enlarged, while 24 patients without obvious enlargement. There＇s obvious difference in FT3, FT4, sTSH, TGA and TMA of patients with thyrotoxic cardiopathy before and 3, 6 and 12 months after treatment （t =2.03-4.17, P 〈0.05）. And there＇s no significant difference among those indexes in 3, 6 and 12 months after treatment. Cure rates of thyrotoxie cardiography was 76.8% （ 63/82 ） , and effective rate was 89.0% （73/82）. Conclusion Radioiodine-131 provides optimistic therapeutic effect for thyrotoxic cardiopathy.